| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 27, 2026 | Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026 | SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billio... |
| Oct 21, 2026 | Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value | 64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care.
More than 10 studies have been selected to highlight th... |
| Sep 29, 2026 | Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596 | HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing
Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties
SHANGHAI, Sept. ... |
| Jun 1, 2026 | Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types | SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Mee... |
| May 12, 2026 | Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology | Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide
Agreements include 13 programs with the potential to address significant unmet patient needs an... |
| Apr 2, 2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| Mar 30, 2026 | Deploying AI as new engine of economic growth | During an informal media scrum outside the main hall of the two sessions, my first ever, one moment stayed with me.
As New Hope Group Chairman Liu Yonghao, a member of the 14th National Committee of the Chinese People's Political Consu... |
| Feb 27, 2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainla... |
| Feb 25, 2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| Oct 20, 2025 | Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power | BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China... |
| Sep 25, 2025 | China’s Hengrui Rises After Licensing Cancer Drug to India's Glenmark in Up to USD1.1 Billion Deal | (Yicai) Sept. 25 -- Shares of Hengrui Pharmaceuticals rose after the Chinese drugmaker agreed to license a class I cancer therapy to a unit of India’s Glenmark Pharmaceuticals for select overseas markets in a deal valued at as much as USD1.... |
| Sep 24, 2025 | Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811) | SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive lice... |
| Sep 5, 2025 | Third of World’s Innovative Drugs Are From China, NDRC’s Vice Chair Says | (Yicai) Sept. 5 -- About one-third of the global innovative drugs are from China, according to the vice chairman of the National Development and Reform Commission.
More than 30 percent of the world’s total number of innovative drugs, drugs ... |
| Sep 5, 2025 | China's Hengrui Rises After Granting Braveheart Bio Heart Drug Rights in Up to USD1.1 Billion Deal | (Yicai) Sept. 5 -- Shares of Hengrui Pharmaceuticals rose after the drugmaker granted US' Braveheart Bio the exclusive global rights outside of China to an innovative heart drug in a deal worth as much as USD1.1 billion, the Chinese fi... |
| Aug 20, 2025 | Hong Kong exchange posts record revenue on listing boom | HONG KONG: Hong Kong's stock exchange operator reported its best half-year revenue on Wednesday (Aug 20), bolstered by a surge in initial public offerings and trading activity.
The Chinese finance hub has weathered a prolonged slump in... |
| Aug 19, 2025 | Innogen bets on longer-lasting GLP-1 drugs to stand out in crowded field | On August 15, Innogen, a pharmaceutical company focused on glucagon-like peptide-1 (GLP-1) therapies, debuted on the Hong Kong Stock Exchange. The company’s shares surged as much as 300% intraday and closed up 200%, pushing its market capit... |
| Aug 4, 2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| Jul 29, 2025 | Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook | Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline.
The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming... |
| Jul 28, 2025 | China's Hengrui Pharma Soars on USD12 Billion GSK Licensing Deal | (Yicai) July 28 -- Shares of Hengrui Pharmaceuticals surged after the Chinese firm announced a licensing deal with multinational drugmaker GSK that could bring in as much as USD12 billion by granting global rights to a portfolio of early-st... |
| Jul 25, 2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong.
In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| Jul 17, 2025 | Sino Biopharm to Buy Out LaNova for Up to USD951 Million, Heralding Potential M&A Wave | (Yicai) July 17 -- Sino Biopharmaceutical said it plans to spend as much as USD951 million to fully acquire LaNova Medicines, a move that may point to more mergers and acquisitions in the Chinese drugs industry.
Sino Biopharm will buy the 9... |
| Jun 20, 2025 | The Dual Faces of China's Tech Landscape: Innovation and Overcapacity | China stands at a crossroads. On one side, a tech revolution is brewing, igniting foreign investment and reshaping global markets. On the other, a shadow looms over its automotive industry, revealing a stark reality of overcapacity and fier... |
| Jun 19, 2025 | Tech innovation key as foreign investors bet on China | An AI robot on display attracts visitors during the recent 2024 World Intelligence Expo in Tianjin. TONG YU/CHINA NEWS SERVICE
BEIJING -- China's surging technology innovation is rewriting the playbook for foreign investors, with the c... |
| Oct 7, 2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| Jul 30, 2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms.
When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |